Four of AstraZeneca’s chronic disease medicines will be available through the U.S. Government’s TrumpRx platform from point of launch: AIRSUPRA® (albuterol/budesonide), BEVESPI AEROSPHERE® (glycopyrrolate and formoterol fumarate), FARXIGA® (dapagliflozin), and XIGDUO® XR (dapagliflozin and metformin HCl extended-release).
In parallel, AstraZeneca has expanded AstraZeneca Direct, the company’s direct-to-consumer platform, to include BEVESPI AEROSPHERE and XIGDUO XR, building on the existing availability of products through the platform. AstraZeneca Direct guides patients to their lowest cost option for accessing their prescribed medicines, including a transparent cash price for eligible patients.
AstraZeneca’s US patient support offerings, including AZ&Me, Copay Savings Programs and the $35 per month out-of-pocket cap on inhaler costs, already help many eligible patients afford their prescribed medicines and remain unchanged.
Patients can access TrumpRx at TrumpRx.gov and AstraZeneca Direct at AstraZenecaDirect.com.
